D&A at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's D&A?
- Corcept Therapeutics (CORT) reported D&A of $598K in Q1 2026.
- How has Corcept Therapeutics's D&A changed year-over-year?
- Corcept Therapeutics's D&A increased by 29.4% year-over-year, from $462K to $598K.
- What is the long-term trend for Corcept Therapeutics's D&A?
- Over 4 years (2021 to 2025), Corcept Therapeutics's D&A has grown at a -21.5% compound annual growth rate (CAGR), from $3.03M to $1.15M.
- What does D&A mean?
- The non-cash expense accounting for the wear and tear or expiration of company assets.
- How do you interpret D&A?
- Higher values indicate significant capital investment in infrastructure or intellectual property.
- How does D&A compare across companies?
- Varies based on the asset-intensity of the pharmaceutical business model.